Arsanis

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

[Read More]

Arsanis closes Series A financing

Tuesday, March 8, 2011

Arsanis, a new biotechnology company that develops anti-infective monoclonal antibody therapeutics, has closed a Series A financing with a total funding of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.

[Read More]